{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:00:44Z","timestamp":1769011244809,"version":"3.49.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.ctrv.2011.11.010","type":"journal-article","created":{"date-parts":[[2012,1,14]],"date-time":"2012-01-14T02:01:14Z","timestamp":1326506474000},"page":"540-548","source":"Crossref","is-referenced-by-count":29,"title":["State-of-the-art classification and multimodality treatment of malignant thymoma"],"prefix":"10.1016","volume":"38","author":[{"given":"Hannah","family":"Koppitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen K.","family":"Rockstroh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinrich","family":"Sch\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Standop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Skowasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Konrad","family":"M\u00fcller-Hermelink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo G.H.","family":"Schmidt-Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2011.11.010_b0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00277-002-0597-6","article-title":"Malignant thymoma: current status of classification and multimodality treatment","volume":"82","author":"Schmidt-Wolf","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0010","series-title":"Thymic neoplasms","author":"Rosenberg","year":"1992"},{"key":"10.1016\/j.ctrv.2011.11.010_b0015","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1200\/JCO.2004.10.113","article-title":"Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis","volume":"22","author":"Strobel","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0020","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.1990.8.8.1419","article-title":"Chemotherapy of invasive thymoma","volume":"8","author":"Fornasiero","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/JTO.0b013e3181f1f62d","article-title":"Epidemiology of thymoma and associated malignancies","volume":"5","author":"Engels","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0030","first-page":"369","article-title":"The pathology and epidemiology of thymoma: an analysis of 2189 cases from the SEER database","volume":"5","author":"Schwartz","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1749-6632.1993.tb22869.x","article-title":"The pathological basis of thymoma-associated myasthenia gravis","volume":"681","author":"Muller-Hermelink","year":"1993","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.ctrv.2011.11.010_b0040","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.athoracsur.2003.10.001","article-title":"Thymic tumors","volume":"77","author":"Detterbeck","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2011.11.010_b0045","unstructured":"Romi F. Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune diseases, article in press, published online 08\/11."},{"key":"10.1016\/j.ctrv.2011.11.010_b0050","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/JTO.0b013e318207cd74","article-title":"Management of thymic tumors: a survey of current practice among members of the European Society of Thoracic Surgeons","volume":"6","author":"Ruffini","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0055","unstructured":"Terzi A, Bertolaccini L, Rizzardi G et al. Usefulness of 18-F FDG PET\/CT in the pre-treatment evaluation of thymic epithelial neoplasms. Lung Cancer, article in press, published online 03\/11."},{"key":"10.1016\/j.ctrv.2011.11.010_b0060","first-page":"370","article-title":"Computed tomography findings predicting invasiveness of thymoma","volume":"5","author":"Marom","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00005382-199907000-00002","article-title":"Tumors of the thymus","volume":"14","author":"Strollo","year":"1999","journal-title":"J Thorac Imaging"},{"key":"10.1016\/j.ctrv.2011.11.010_b0070","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0039-6109(16)40093-9","article-title":"Thymoma: factors influencing prognosis","volume":"53","author":"Bernatz","year":"1973","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.ctrv.2011.11.010_b0075","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/1097-0142(196211\/12)15:6<1224::AID-CNCR2820150621>3.0.CO;2-V","article-title":"Thymoma and other tumors of the thymus. An analysis of 107 cases","volume":"15","author":"Lattes","year":"1962","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0080","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0046-8177(78)80131-2","article-title":"Thymic hyperplasia and neoplasia: a review of current concepts","volume":"9","author":"Levine","year":"1978","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0085","first-page":"2","article-title":"Primary thymic epithelial neoplasms: spectrum of differentiation and histological features","volume":"16","author":"Suster","year":"1999","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0090","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1365-2559.2000.00860.x","article-title":"Towards a histogenetic classification of thymic epithelial tumours?","volume":"36","author":"Muller-Hermelink","year":"2000","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2011.11.010_b0095","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archinte.1974.00320200184029","article-title":"The spectrum of diseases associated with thymoma. Coincidence or syndrome?","volume":"134","author":"Souadjian","year":"1974","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ctrv.2011.11.010_b0100","first-page":"18","article-title":"Primary carcinomas of the thymus gland","volume":"16","author":"Ritter","year":"1999","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0105","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-3-642-82480-7_7","article-title":"Pathology of thymic epithelial tumors","volume":"75","author":"Muller-Hermelink","year":"1986","journal-title":"Curr Top Pathol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0110","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00001622-200009000-00007","article-title":"Thymoma","volume":"12","author":"Muller-Hermelink","year":"2000","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0115","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/ajcp\/111.6.826","article-title":"Thymoma, atypical thymoma and thymic carcinoma. A novel conceptual approach to the classification of thymic epithelial neoplasms","volume":"111","author":"Suster","year":"1999","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0120","series-title":"Histological typing of tumors of the thymus","author":"Rosai","year":"1999"},{"key":"10.1016\/j.ctrv.2011.11.010_b0125","series-title":"World Health Organization classification of tumors. Pathology and genetics of tumours of the lung thymus and heart","author":"Travis","year":"2004"},{"key":"10.1016\/j.ctrv.2011.11.010_b0130","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/cncr.10226","article-title":"The World Health Organization histological classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients","volume":"94","author":"Okumura","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0135","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/1097-0142(19940715)74:2<606::AID-CNCR2820740212>3.0.CO;2-T","article-title":"Thymoma. Histological subclassification is an independent prognostic factor","volume":"74","author":"Quintanilla-Martinez","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0140","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cncr.10665","article-title":"New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China","volume":"95","author":"Chen","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0002-9440(10)64536-1","article-title":"Recurrent genetic aberrations in thymoma and thymic carcinoma","volume":"157","author":"Zettl","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0150","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0002-9440(10)63031-3","article-title":"Thymic epithelial tumors can develop along two different pathogenetic pathways","volume":"159","author":"Zhou","year":"2001","journal-title":"AM J Pathol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0155","first-page":"3708","article-title":"Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas","volume":"63","author":"Inoue","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2011.11.010_b0160","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00737071","article-title":"Thymoma and thymic carcinoma. Relation of thymoma epithelial cells to the cortical and medullary differentiation of thymus","volume":"2007","author":"Marino","year":"1985","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2011.11.010_b0165","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/00000478-199212000-00003","article-title":"Well-differentiated thymic carcinoma. An organotypical low-grade carcinoma with relationship to cortical thymoma","volume":"16","author":"Kirchner","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0170","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1440-1827.1994.tb02936.x","article-title":"A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma","volume":"44","author":"Koga","year":"1994","journal-title":"Pathol Int"},{"key":"10.1016\/j.ctrv.2011.11.010_b0175","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1097\/JTO.0b013e31821e8cff","article-title":"The Masaoka-Koga stage classification for thymic malignancies clarification and definition of terms","volume":"6","author":"Detterbeck","year":"2011","journal-title":"J Thorax Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0180","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/1097-0142(19911101)68:9<1984::AID-CNCR2820680923>3.0.CO;2-P","article-title":"A tentative tumor-node-metastasis classification of thymoma","volume":"68","author":"Yamakawa","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0185","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/JTO.0b013e3181f20f3b","article-title":"Tumor-node metastasis staging system for thymic epithelial tumors","volume":"5","author":"Kondo","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0190","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/JTO.0b013e3181f20c05","article-title":"Staging system of thymoma","volume":"5","author":"Masaoka","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0195","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2011.11.010_b0200","first-page":"1507","article-title":"Chromosome 6 suffers frequent and multiple aberrations in thymoma","volume":"161","author":"Inoue","year":"2002","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0205","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/JTO.0b013e3181f209a8","article-title":"Thymoma and thymic carcinoma. Molecular pathology and targeted therapy","volume":"5","author":"Strobel","year":"2002","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0210","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas clin cancer","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2011.11.010_b0215","first-page":"3","article-title":"A 25-year thymoma treatment review","volume":"19","author":"Whooley","year":"2000","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2011.11.010_b0220","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1097\/JTO.0b013e31821ea553","article-title":"Standard terms, definitions, and policies for minimally invasive resection of thymoma","volume":"6","author":"Toker","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0225","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1052-3359(25)00578-2","article-title":"Surgery for thymoma","volume":"11","author":"Port","year":"2001","journal-title":"Chest Surg Clin North Am"},{"key":"10.1016\/j.ctrv.2011.11.010_b0230","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.athoracsur.2008.03.055","article-title":"The role of surgery in the management of thymoma: a systematic review","volume":"86","author":"Davenport","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2011.11.010_b0235","first-page":"367","article-title":"Robotic thymectomy for thymoma: when and why?","volume":"5","author":"Ruckert","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0240","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1096-9098(199609)63:1<17::AID-JSO4>3.0.CO;2-T","article-title":"Preoperative radiotherapy and surgery for advanced thymoma with invasion to the great vessels","volume":"63","author":"Akaodi","year":"1996","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0245","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1200\/JCO.1988.6.11.1722","article-title":"Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection","volume":"6","author":"Curran","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0250","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0003-4975(91)90478-9","article-title":"Thymoma: results of 241 operated cases","volume":"51","author":"Maggi","year":"1991","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2011.11.010_b0255","unstructured":"Patel S, Macdonald OK, Nagda S et al. Evaluation of the role of radiation therapy in the management of malignant thymoma. Int J Radiat Oncol Biol Phys, article in press, published online 05\/11."},{"key":"10.1016\/j.ctrv.2011.11.010_b0260","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ijrobp.2009.02.016","article-title":"Postoperative radiotherapy after surgical resection of thymoma. Differing roles in localized and regional disease","volume":"76","author":"Forquer","year":"2010","journal-title":"Int J Radiat Incol Biol Phys"},{"key":"10.1016\/j.ctrv.2011.11.010_b0265","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/JTO.0b013e31818e105c","article-title":"Thymoma. A focus on current therapeutic management","volume":"4","author":"Girard","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0270","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2003.12.010","article-title":"Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy and consolidation chemotherapy for unresectable malignant thymomas: final report","volume":"44","author":"Kim","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0275","unstructured":"http:\/\/cancernet.nci.nih.gov\/, Thymoma, recurrent thymoma and thymic carcinoma."},{"key":"10.1016\/j.ctrv.2011.11.010_b0280","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00000421-199308000-00014","article-title":"EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma","volume":"16","author":"Bonomi","year":"1993","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0285","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1002\/1097-0142(19940515)73:10<2491::AID-CNCR2820731007>3.0.CO;2-6","article-title":"Thymoma. A retrospective study of 87 cases","volume":"73","author":"Park","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0290","first-page":"300","article-title":"Ifosfamide monotherapy demonstrates high activity in malignant thymoma","volume":"10","author":"Harper","year":"1991","journal-title":"Proc ASCO"},{"key":"10.1016\/j.ctrv.2011.11.010_b0295","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1999.17.9.2737","article-title":"Treatment of invasive thymoma with single-agent ifosfamide","volume":"17","author":"Highley","year":"1999","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2011.11.010_b0300","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/ejso.2001.1197","article-title":"Thymic carcinoma: a report of 13 cases","author":"Lucchi","year":"2001","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0305","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0022-5223(19)34092-9","article-title":"Chemotherapy and operation for noninvasive thymoma","volume":"106","author":"Rea","year":"1993","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ctrv.2011.11.010_b0310","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/1097-0142(19910815)68:4<706::AID-CNCR2820680407>3.0.CO;2-H","article-title":"Neoadjuvant chemotherapy, surgery and postoperative radiation therapy for invasive thymoma","volume":"68","author":"Macchiarini","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0315","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/BF03218184","article-title":"Thymic carcinoma. Outcome of treatment including surgical resection","volume":"48","author":"Takahashi","year":"2000","journal-title":"Jpn J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ctrv.2011.11.010_b0320","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0360-3016(99)00514-3","article-title":"Stage III thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future study","volume":"46","author":"Myojin","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2011.11.010_b0325","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0003-4975(95)00983-3","article-title":"Surgical treatment for invasive thymoma, especially when the superior vena cava is invaded","volume":"61","author":"Yagi","year":"1996","journal-title":"Ann thorac Surg"},{"key":"10.1016\/j.ctrv.2011.11.010_b0330","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/JTO.0b013e3181f20f27","article-title":"Surgical treatment of recurrent thymomas","volume":"5","author":"Lucchi","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0335","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.athoracsur.2008.11.022","article-title":"Adjuvant radiotherapy for thymic epithelial tumors. A systematic review and meta-analysis","volume":"87","author":"Korst","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2011.11.010_b0340","unstructured":"McKenna BP, Barnes MM, Glatstein E et al., Malignancies of the thymus, Philadelphia, PA, 1989."},{"key":"10.1016\/j.ctrv.2011.11.010_b0345","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.1999.17.7.2280","article-title":"Thymoma: state of the art","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0350","first-page":"73","article-title":"Current approaches to the treatment of thymoma","volume":"31","author":"Loehrer","year":"1999","journal-title":"Ann Med"},{"key":"10.1016\/j.ctrv.2011.11.010_b0355","first-page":"46","article-title":"Adjuvant therapy in invasive thymoma: an audit of cases treated over an 8year period","volume":"36","author":"Agrawal","year":"1999","journal-title":"Ind J Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0360","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0360-3016(79)90042-7","article-title":"The management of malignant thymoma with radiation therapy","volume":"5","author":"Ariaratnam","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2011.11.010_b0365","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/bjs.1800590708","article-title":"The role of radiotherapy in the management of malignant thymoma","volume":"59","author":"Penn","year":"1972","journal-title":"Br J Surg"},{"key":"10.1016\/j.ctrv.2011.11.010_b0370","first-page":"1483","article-title":"Feasibility of multimodality therapy including extended resections in stage IVa thymoma","volume":"6","author":"Huang","year":"2007","journal-title":"J Thor Cardiovasc Surg"},{"key":"10.1016\/j.ctrv.2011.11.010_b0375","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejcts.2010.12.064","article-title":"Long-term outcome of pleuropneumonectomy for Masaoka stage IVa thymoma","volume":"39","author":"Fabre","year":"2011","journal-title":"Eur J Cardiothor Surg"},{"key":"10.1016\/j.ctrv.2011.11.010_b0380","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1510\/icvts.2010.255307","article-title":"Induction chemotherapy, cytoreductive surgery and intraoperative hyperthermic pleural irrigation in patients with stage IVa thymoma","volume":"12","author":"Belcher","year":"2011","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.ctrv.2011.11.010_b0385","first-page":"368","article-title":"Fifteen years experience with pleural perfusion thermochemotherapy for thymic epithelial malignancies with pleural spread","volume":"5","author":"Yellin","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0390","first-page":"367","article-title":"Radical pleurectomy and photodynamic therapy as a treatment for stage IVa thymic tumors","volume":"5","author":"Hsieh","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0395","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial","volume":"15","author":"Loehrer","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0400","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"14","author":"Giaccone","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0405","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0410","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","article-title":"Chemotherapy for invasive thymoma. A 13-year experience","volume":"68","author":"Fornasiero","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0415","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/oxfordjournals.annonc.a058527","article-title":"Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide (ADOC) in invasive thymomas: results in six patients","volume":"4","author":"Berruti","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0420","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0425","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.lungcan.2009.03.031","article-title":"Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma","volume":"67","author":"Igawa","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0430","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jjco\/hyr089","article-title":"Combination chemotherapy with Carboplatin and Paclitaxel for advanced thymic cancer","volume":"41","author":"Furugen","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0435","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/JTO.0b013e3181db3dee","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience","volume":"5","author":"Grassin","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0440","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0445","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.bjc.6605731","article-title":"A phase II trial of dose-dense chemotherapy, followed by surgical resection and\/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)","volume":"103","author":"Kunitoh","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0450","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1510\/icvts.2010.264036","article-title":"Number of recurrent lesions is a prognostic factor in recurrent thymoma","volume":"13","author":"Yano","year":"2011","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.ctrv.2011.11.010_b0455","unstructured":"http:\/\/www.itmig.org."},{"key":"10.1016\/j.ctrv.2011.11.010_b0460","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0167-8140(92)90227-L","article-title":"Aggressive treatment of intrathoracic recurrences of thymoma","volume":"24","author":"Urgesi","year":"1992","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0465","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/cncr.10374","article-title":"Somatostatin analogs and prednisone in advanced refractory thymic tumors","volume":"94","author":"Palmieri","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0470","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0475","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000082626","article-title":"Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma","volume":"50","author":"Oguri","year":"2004","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ctrv.2011.11.010_b0480","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1097\/JTO.0b013e3181f13682","article-title":"Standard outcome measures for thymic malignancies","volume":"5","author":"Huang","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0485","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/JTO.0b013e3181f22d01","article-title":"International thymic malignancies interest group. A way forward","volume":"5","author":"Detterbeck","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0490","first-page":"288","article-title":"Invasive thymoma successfully treated with high-dose chemotherapy followed by peripheral blood stem cell transplantation (PBSCT)","volume":"36","author":"Iwasaki","year":"1998","journal-title":"Nihon Kokyuiki Gakkai Zasshi"},{"key":"10.1016\/j.ctrv.2011.11.010_b0495","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(05)70285-0","article-title":"Non-myeloablative allogenic haematopoietic stem-cell transplantation for treatment of metastatic invasive thymoma","volume":"6","author":"Numata","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0500","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/sj.bmt.1703181","article-title":"High-dose carboplatin with etoposide in patients with recurrent thymoma: the Indiana University experience","volume":"28","author":"Hanna","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2011.11.010_b0505","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00000478-200101000-00013","article-title":"Spindle cell and mixed spindle\/lymphocytic thymomas: an integrated clinicopathologic and immunohistochemical study of 81 cases","volume":"25","author":"Pan","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0510","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CND.0b013e31819a8403","article-title":"Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review","volume":"10","author":"Nelson","year":"2009","journal-title":"J Clin Neuromuscul Dis."},{"key":"10.1016\/j.ctrv.2011.11.010_b0515","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00002371-199510000-00005","article-title":"A phase II trial of subcutaneously administered recombinant human interleukin-2 in patients with relapsed\/refractory thymoma","volume":"18","author":"Gordon","year":"1995","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0520","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/0140-6736(90)91415-7","article-title":"Effectiveness of interleukin-2 in invasive lymphoepithelial thymoma","volume":"335","author":"Berthaud","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2011.11.010_b0525","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s00280-004-0816-z","article-title":"Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors","volume":"54","author":"Tran","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0530","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/02841860500355983","article-title":"The potential of proton beam radiation therapy in malignant lymphoma, thymoma and sarcoma","volume":"44","author":"Bjork-Eriksson","year":"2005","journal-title":"Acta Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2011.11.010_b0535","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.bjc.6603321","article-title":"A phase I study of pemetrexed (LY231514) supplement with folate and vitamin B12 in Japanese patients with solid tumors","volume":"95","author":"Nakagawa","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0540","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors","volume":"14","author":"Steele","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2011.11.010_b0545","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0550","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","article-title":"KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas","volume":"202","author":"Pan","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0555","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Strobel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2011.11.010_b0560","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2006.08.8963","article-title":"Dasatinib induces a response in malignant thymoma","volume":"24","author":"Chuah","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0565","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.1200\/jco.2008.26.15_suppl.8116","article-title":"Imatinib for the treatment of thymic carcinoma","volume":"26","author":"Salter","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0570","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0575","first-page":"368","article-title":"A phase II study of saracatinib (AZD0530) a SRC inhibitor administered orally daily to patients with advanced thymic malignancies","volume":"5","author":"Wakelee","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0580","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","article-title":"Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience","volume":"103","author":"Strobel","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0585","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","article-title":"Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report","volume":"26","author":"Li","year":"2009","journal-title":"Med Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0590","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","article-title":"Long lasting response to the multikinase inhibitor Bay 43\u20139006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma","volume":"4","author":"Bisagni","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0595","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","article-title":"Cetuximab is an active treatment of metastatic and chemorefractory thymoma","volume":"12","author":"Palmieri","year":"2007","journal-title":"Front Biosci"},{"key":"10.1016\/j.ctrv.2011.11.010_b0600","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","article-title":"Response of thymoma to cetuximab","volume":"8","author":"Farina","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0605","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1200\/jco.2005.23.16_suppl.7068","article-title":"Phase II study of gefitinib treatment in advanced thymic malignancies","volume":"23","author":"Kurup","year":"2005","journal-title":"J Clin Oncol ASCO"},{"key":"10.1016\/j.ctrv.2011.11.010_b0610","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/annonc\/mdn388","article-title":"Response of malignant thymoma to erlotinib","volume":"19","author":"Christodoulou","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0615","doi-asserted-by":"crossref","first-page":"19087","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0620","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0625","first-page":"169","article-title":"Expression of angiogenesis-related biomarkers in thymic epithelial tumors","volume":"5","author":"Marino","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2011.11.010_b0630","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1002\/cncr.25367","article-title":"Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas","volume":"116","author":"Zucali","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0635","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-10-1689","article-title":"Heat shock Protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors","volume":"17","author":"Breinig","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2011.11.010_b0640","doi-asserted-by":"crossref","first-page":"e17525","DOI":"10.1200\/jco.2010.28.15_suppl.e17525","article-title":"Phase II study of the insulin-like growth factor-1 receptor antibody cixutumumab in patients with thymoma and thymic carcinoma","volume":"28","author":"Rajan","year":"2010","journal-title":"J Clin Oncol ASCO"},{"key":"10.1016\/j.ctrv.2011.11.010_b0645","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1158\/1078-0432.CCR-07-1118","article-title":"Phase I dose escalation study of the anti-insulin-like growth factor-i receptor monoclonal antibody cp-751, 871 in patients with refractory solid tumors","volume":"13","author":"Haluska","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2011.11.010_b0650","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/ctrv.1999.0159","article-title":"Malignant thymoma: current status and future directions","volume":"26","author":"Lara","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2011.11.010_b0655","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Tanioka. Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.11.010_b0660","series-title":"Thymome","author":"Sch\u00fctte","year":"1995"},{"key":"10.1016\/j.ctrv.2011.11.010_b0665","unstructured":"http:\/\/www.clinicaltrials.gov."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737211002490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737211002490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T19:52:00Z","timestamp":1742327520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737211002490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":133,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0305737211002490"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2011.11.010","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}